InflaRx (NASDAQ:IFRX) Given New $10.00 Price Target at Guggenheim

InflaRx (NASDAQ:IFRX) had its price target increased by stock analysts at Guggenheim from $7.00 to $10.00 in a research note issued on Wednesday, Marketbeat reports. The brokerage currently has a “buy” rating on the stock.

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st.

InflaRx Price Performance

IFRX stock opened at $1.25 on Wednesday. InflaRx has a fifty-two week low of $1.13 and a fifty-two week high of $2.82. The stock has a market capitalization of $83.92 million, a price-to-earnings ratio of -1.16 and a beta of 1.98. The business’s fifty day moving average price is $1.83 and its two-hundred day moving average price is $1.89.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.18. InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. Research analysts expect that InflaRx will post -1.04 EPS for the current year.

Institutional Trading of InflaRx

Large investors have recently modified their holdings of the stock. Two Sigma Securities LLC bought a new stake in InflaRx in the 4th quarter valued at about $28,000. Walleye Capital LLC bought a new position in InflaRx in the fourth quarter worth approximately $51,000. Cubist Systematic Strategies LLC acquired a new stake in InflaRx in the fourth quarter valued at approximately $55,000. Geode Capital Management LLC increased its holdings in shares of InflaRx by 32.8% during the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after acquiring an additional 11,900 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its position in shares of InflaRx by 20.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after purchasing an additional 19,000 shares during the period. Institutional investors and hedge funds own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.